Delft University of Technology (TU Delft)

“What is life? How does a living cell emerge from lifeless molecules?” wondered a multidisciplinary team of Dutch scientists. To answer these questions the research team, led by the TU Delft, aims to build a living synthetic cell from lifeless biomolecules, using laboratory evolution and artificial intelligence for the first time. The ten-year research programme to do so, entitled “Evolving life from non-life” or simply “EVOLF”, was awarded 40 million euro by the Dutch Research Council (NWO) as part of the Summit grants scheme.
Co-applicant Gijsje Koenderink (TU Delft): “It is fascinating, all lifeforms consist of cells, and all cells consist of molecules. Notably, these molecules are not alive, but a cell is. How does a living cell emerge from lifeless molecules? How many components are minimally required and how should they be wired to establish a living cell? These are the big questions we will try to answer in the next ten years.”
New approach EVOLF
The EVOLF team aims to bridge the gap between non-life and life by building a living synthetic cell from lifeless biomolecules. This approach builds on their earlier pioneering work in biophysics and biochemistry, in which the scientists already created cellular modules for a minimal genome, metabolism, and cell division. This work has laid the foundation for the construction of an actual living synthetic cell. With an entirely new approach that uses artificial intelligence and directed laboratory evolution to accelerate the building of synthetic cells, the team hopes to answer the question of how life works.
Main applicant Cees Dekker (TU Delft): “Our dream is to create a living cell from lifeless molecules. Using artificial intelligence, we can scan parameters much more effectively to optimise complex networks of biochemical reactions. Our goal is to integrate cellular functions into one unified synthetic cell that can autonomously replicate, communicate and evolve. In addition, we will intimately connect the scientific work with philosophical and ethical research.”
Dekker emphasizes: “In our ‘living lab’, philosophers and humanities scholars will work together with scientists on articulating a new definition of life as well as responsible research guidelines to establish conditions where humans remain in firm control of synthetic life.”
Partners consortium EVOLF and Summit grant
The EVOLF-consortium consists of scientists of TU Delft, AMOLF, University of Groningen, Radboud University, Wageningen University & Research, Hubrecht Institute, and VU Amsterdam. The Summit grant will allow the consortium to hire 100 PhD students, postdocs, technicians as well as install critical infrastructure and enabling technologies. By realizing the dream of building a synthetic cell, which Dekker calls “one of the grand challenges of this century”, the consortium aims for a breakthrough in the life sciences, on par with discovering the double-helix of DNA or decoding the human genome.

Researchers at Ruhr University Bochum have shown how zinc inhibits [FeFe]-hydrogenases, enzymes that produce hydrogen, by binding two surface histidines near a known proton transport pathway. One histidine acts as a molecular pendulum, receiving a proton at the enzyme surface and delivering it inward. Replacing it slowed hydrogen production; replacing the other left the enzyme active but zinc insensitive.

Researchers at the Institute of Science Tokyo have developed Chol-HDO[PMO], a cholesterol-conjugated heteroduplex oligonucleotide pairing a phosphorodiamidate morpholino oligomer with complementary RNA. Delivered into cerebrospinal fluid, it silenced or modulated target genes in mice with up to 16-fold greater potency than conventional antisense designs, and the effect was long lasting. It avoided acute neurotoxicity, weight loss and immune reactions.

High-speed atomic force microscopy has revealed that the amount of PD-L1 on cancer-derived extracellular vesicles does not indicate how accessible the protein is to antibodies. Researchers at Kanazawa University imaged individual vesicles from two breast cancer cell lines in liquid, finding that over 80 percent of high-PD-L1 vesicles held antibodies persistently, while most low-PD-L1 vesicles showed no stable binding.
This week in nanotech
$24.4M raised
5 funding rounds · 33 deals tracked
New products
Nion-compatible In Situ STEM Holders for Electrical BiasingHummingbird Scientific Featured
Orion Sputtering Deposition SystemsAJA International Featured
Fe85Cr4Mo8V2C1 wire filler materialLeibniz Institute for Solid State and Materials Research Dresden - IFW DresdenMarket insights
Last 30 days: Quantum Technologies drew the most money: $3.17B.
Money raised per month